Phenothiazine-based chalcones as potential dual-target inhibitors toward cholinesterases (AChE, BuChE) and monoamine oxidases (MAO-A, MAO-B)

ArticleAçık Erişim

Özet

Chalcones targeting neurodegenerative diseases have been known as attractive structures in drug design and discovery. In this study, phenothiazine-based chalcones as ChEs and MAOs inhibitors were designed and synthesized via base-catalyzed Claisen-Schmidt condensation, and chemical structures of the compounds were elucidated by NMRs and HRMS. Compounds 3 and 9 showed promising inhibition potency against AChE enzyme with IC50 values of 0.221 μM and 0.053 μM while compound 9 displayed remarkable inhibition potency toward MAO-B enzyme with IC50 value of 0.048 μM. Compound 9, as a dual-target inhibitor, selectively inhibited AChE and MAO-B enzymes. This promising behavior is an advantage for the compound since MAO-B and AChE inhibition have a role in Alzheimer's disease. Fused tricyclic ring systems such as phenothiazine incorporated with chalcone moiety being multitargeting ligands may help scientists for the rational design of novel lead compounds targeting neurodegenerative illnesses. © 2020 Wiley Periodicals LLC.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/13155Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1002/jhet.4156Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorYamali, Cem
dc.contributor.authorEngin, Feyza Sena
dc.contributor.authorBilginer, Sinan
dc.contributor.authorTugrak, Mehtap
dc.contributor.authorOzmen Ozgun, Dilan
dc.contributor.authorOzli, Gulsen
dc.contributor.authorLevent, Serkan
dc.contributor.authorSaglik, Begum Nurpelin
dc.contributor.authorOzkay, Yusuf
dc.contributor.authorGul, Halise Inci
dc.date.accessioned2026-10-18T20:27:59.842018522Z
dc.date.available2026-10-18T20:27:59.842018522Z
dc.date.issued2021
dc.description.abstractChalcones targeting neurodegenerative diseases have been known as attractive structures in drug design and discovery. In this study, phenothiazine-based chalcones as ChEs and MAOs inhibitors were designed and synthesized via base-catalyzed Claisen-Schmidt condensation, and chemical structures of the compounds were elucidated by NMRs and HRMS. Compounds 3 and 9 showed promising inhibition potency against AChE enzyme with IC50 values of 0.221 μM and 0.053 μM while compound 9 displayed remarkable inhibition potency toward MAO-B enzyme with IC50 value of 0.048 μM. Compound 9, as a dual-target inhibitor, selectively inhibited AChE and MAO-B enzymes. This promising behavior is an advantage for the compound since MAO-B and AChE inhibition have a role in Alzheimer's disease. Fused tricyclic ring systems such as phenothiazine incorporated with chalcone moiety being multitargeting ligands may help scientists for the rational design of novel lead compounds targeting neurodegenerative illnesses. © 2020 Wiley Periodicals LLC.
dc.identifier.doi10.1002/jhet.4156
dc.identifier.eissn1943-5193
dc.identifier.endpage171
dc.identifier.issn0022-152X
dc.identifier.issue1
dc.identifier.scopus2-s2.0-85092590337
dc.identifier.startpage161
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/13155
dc.identifier.volume58
dc.identifier.wosWOS:000577946000001
dc.language.isoen
dc.publisherHeteroCorporation
dc.relation.ispartofJournal of Heterocyclic Chemistry
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subject1 (10h phenothiazin 2 yl) 3 aryl 2 propen 1 one derivative
dc.subject1 (10h phenothiazine 2 yl) 3 (2 fluorophenyl)prop 2 en 1 one
dc.subject1 (10h phenothiazine 2 yl) 3 (2,4 dichlorophenyl)prop 2 en 1 one
dc.subject1 (10h phenothiazine 2 yl) 3 (3 bromophenyl)prop 2 en 1 one
dc.subject1 (10h phenothiazine 2 yl) 3 (3 fluorophenyl)prop 2 en 1 one
dc.subject1 (10h phenothiazine 2 yl) 3 (3 nitrophenyl)prop 2 en 1 one
dc.subject1 (10h phenothiazine 2 yl) 3 (3,4 dichlorophenyl)prop 2 en 1 one
dc.subject1 (10h phenothiazine 2 yl) 3 (3,4 methylenedioxyphenyl)prop 2 en 1 one
dc.subject1 (10h phenothiazine 2 yl) 3 (4 benzyloxyphenyl)prop 2 en 1 one
dc.subject1 (10h phenothiazine 2 yl) 3 (4 chlorophenyl)prop 2 en 1 one
dc.subject1 (10h phenothiazine 2 yl) 3 (4 fluorophenyl)prop 2 en 1 one
dc.subject1 (10h phenothiazine 2 yl) 3 (4 methoxyphenyl)prop 2 en 1 one
dc.subject1 (10h phenothiazine 2 yl) 3 (4 methylphenyl)prop 2 en 1 one
dc.subject1 (10h phenothiazine 2 yl) 3 (4 nitrophenyl)prop 2 en 1 one
dc.subject1 (10h phenothiazine 2 yl) 3 (4 trifluoromethylphenyl)prop 2 en 1 one
dc.subject1 (10h phenothiazine 2 yl) 3 (thiophene 2 yl)prop 2 en 1 one
dc.subject1 (10h phenothiazine 2 yl) 3 phenyl prop 2 en 1 one
dc.subjectacetylcholinesterase
dc.subjectamine oxidase (flavin containing) isoenzyme A
dc.subjectamine oxidase (flavin containing) isoenzyme B
dc.subjectchalcone derivative
dc.subjectcholinesterase
dc.subjectclorgyline
dc.subjectdonepezil
dc.subjectphenothiazine derivative
dc.subjectselegiline
dc.subjecttacrine
dc.subjectunclassified drug
dc.subjectAlzheimer disease
dc.subjectArticle
dc.titlePhenothiazine-based chalcones as potential dual-target inhibitors toward cholinesterases (AChE, BuChE) and monoamine oxidases (MAO-A, MAO-B)
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus29
rdl.citation.wos29
rdl.oa.statusgreen
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)
rdl.wos.indexIndex Chemicus (IC)